Observational Study of Long Acting Injectable Medications (LAIs) in Schizophrenia (OASIS)

Completed

Conditions studied: Schizophrenia

In brief

The objectives of this study are to describe characteristics, treatment patterns, and outcomes of patients with schizophrenia newly initiated on 1 of 4 FDA-approved atypical Long Acting Injectable (LAI) antipsychotics (ABILIFY MAINTENA®, ARISTADA®, INVEGA SUSTENNA® or RISPERDAL CONSTA®)

Key facts

Study ID

NCT03919994

Run by

Alkermes, Inc.

People needed

338

Starts

2019-03-28

Expected to finish

2023-01-04

Last updated by the study team

2023-02-02

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Must be able to speak, read and understand English
• Diagnosis of schizophrenia as defined by the treating clinician
• Newly initiating treatment with 1 of 4 atypical Long Acting Injectables (LAIs): Abilify Maintena, Aristada, Invega Sustenna, or Risperdal Consta)
• Additional criteria may apply

You may not qualify if…

• Currently participating or planning to participate in an interventional clinical study, or has completed participation in an interventional clinical study within 30 days before enrollment
• In the opinion of the investigator, is currently an imminent danger to himself/herself. [Note: A prior history of suicidal ideation or suicidal attempt is not exclusionary.]
• Additional criteria may apply

Where it is running

• Alkermes Investigational Site — Costa Mesa, California, United States
• Alkermes Investigational Site — El Cajon, California, United States
• Alkermes Investigational Site — Granada Hills, California, United States
• Alkermes Investigational Site — Oceanside, California, United States
• Alkermes Investigational Site — Panorama City, California, United States
• Alkermes Investigational Site — San Bernardino, California, United States
• Alkermes Investigational Site — Dayville, Connecticut, United States
• Alkermes Investigational Site — Hialeah, Florida, United States
• Alkermes Investigational Site — Hialeah, Florida, United States
• Alkermes Investigational Site — Lauderdale Lakes, Florida, United States
• Alkermes Investigational Site — Miami, Florida, United States
• Alkermes Investigational Site — Miami Gardens, Florida, United States
• Alkermes Investigational Site — Orlando, Florida, United States
• Alkermes Investigational Site — Panama City, Florida, United States
• Alkermes Investigational Site — Tallahassee, Florida, United States
• Alkermes Investigational Site — Augusta, Georgia, United States
• Alkermes Investigational Site — Lawrenceville, Georgia, United States
• Alkermes Investigational Site — Honolulu, Hawaii, United States
• Alkermes Investigational Site — Honolulu, Hawaii, United States
• Alkermes Investigational Site — Schaumburg, Illinois, United States
• Alkermes Investigational Site — Springfield, Illinois, United States
• Alkermes Investigational Site — Indianapolis, Indiana, United States
• Alkermes Investigational Site — Bel Air, Maryland, United States
• Alkermes Investigational Site — Boston, Massachusetts, United States
• Alkermes Investigational Site — Tucson, Arizona, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.